Celltrion to seek new drug, CDMO partners at int'l pharmaceutical exhibition in Milan
Celltrion will use one of the world's largest pharmaceutical trade shows next month to seek partners in new drug development, contract manufacturing and supply chains, the Korean biopharmaceutical company said Tuesday. The company will take part in CPHI Worldwide, which runs Oct. 6-8 in Milan. Now in its 37th year, the event covers pharmaceutical manufacturing, supply chains and contract…
Celltrion plans to seek new drug development, contract manufacturing, and supply chain partners at the upcoming CPHI Worldwide pharmaceutical trade show in Milan, the Korean biopharmaceutical company announced on Tuesday. The company will participate in the 37th edition of the CPHI Worldwide event, which takes place from October 6-8 and attracts more than 60,000 industry professionals from around 2,400 companies across 170 countries.
Celltrion, renowned for its biosimilars, aims to explore partnerships in oncology, obesity, metabolic diseases, and autoimmune diseases. The company recently began making progress in new drug research in these areas, positioning itself for global drug development. As the demand for its core products escalates, Celltrion intends to bolster its existing alliances with overseas raw material suppliers and contract manufacturers.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
